Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
Zacks News
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
by Zacks Equity Research
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
by Zacks Equity Research
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
by Zacks Equity Research
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
Charles River (CRL) Partners to Reduce Animal Research Usage
by Zacks Equity Research
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
by Zacks Equity Research
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
ICLR vs. CRL: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. CRL: Which Stock Is the Better Value Option?
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?